Overall, these results suggest the regulation of the TNF signaling pathway by Disitamab Vedotin at the mRNA level in bladder cancer cells and also indicate that different bladder cancer cell lines may respond slightly differently to Disitamab Vedotin. Here, TNF is linked to urinary bladder carcinoma.